Percutaneous coronary intervention in patients undergoing transcatheter aortic valve implantation: too early to draw conclusions
EuroIntervention 2018;14:e487-e489 published online e-edition August 2018. DOI: 10.4244/EIJV14I5A85
Jacob Lønborg, MD, PhD, DMSc; Thomas Engstrøm, MD, PhD, DMSc; Ole De Backer, MD, PhD; Lars Søndergaard*, MD, DMSc
Department of Cardiology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
Severe aortic stenosis (AS) is frequently present in the ageing population and is related to mortality and morbidity. Traditionally, this disease has been treated with surgical aortic valve replacement (SAVR); however, during the last decade the field has been revolutionised by the less invasive transcatheter aortic valve implantation (TAVI). The number of TAVI procedures is increasing rapidly and, as the boundaries of TAVI are continuously pushed, there is an increased need for knowledge on how to deal with comorbidities.
Concomitant coronary artery disease (CAD) is a frequent comorbidity observed in up to 50% of patients selected for TAVI1. The ...
